title: Down-Regulation of miR-186 Correlates with Poor Survival in de novo Acute Myeloid Leukemia.
abstract: BACKGROUND
  MicroRNA-186 (miR-186) plays an important role in the pathogenesis of several cancers. Our study was intended to investigate the expression status and the prognostic implication of miR-186 in acute myeloid leukemia (AML).
  
  
  METHODS
  Real-time quantitative PCR was carried out in 112 de novo AML patients and 28 controls.
  
  
  RESULTS
  The level of miR-186 expression in AML was significantly down-regulated compared to normal controls (p < 0.001). Patients with low miR-186 expression presented significantly older age than those with high miR-186 expression (p = 0.004). MiR-186high patients had a significantly higher frequency of CEBPA mutation than miR-186low patients (20% and 4%, respectively, p = 0.022). In addition, miR-186low patients had a significantly lower complete remission (CR) rate (30% vs. 53%, respectively, p = 0.028) than miR-186high patients. Moreover, miR-186low patients showed significantly shorter overall survival (OS) time than miR-186high patients in both whole AML and non-M3 patients (p = 0.023 and 0.026, respectively). Additionally, the adverse prognostic impact of miR-186 down-regulation was also shown in both whole AML and non-M3 patients without CEBPA mutation (p = 0.017 and 0.023, respectively).
  
  
  CONCLUSIONS
  Our study suggests that miR-186 down-regulation is a frequent event and predicts poor prognosis in de novo AML patients.
authors.forename: Ting-juan
authors.initials: TJ
authors.lastname: Zhang
authors.forename: Yu-Xin
authors.initials: YX
authors.lastname: Wang
authors.forename: Dong-Qin
authors.initials: DQ
authors.lastname: Yang
authors.forename: Dong-ming
authors.initials: DM
authors.lastname: Yao
authors.forename: Lei
authors.initials: L
authors.lastname: Yang
authors.forename: Jing-dong
authors.initials: JD
authors.lastname: Zhou
authors.forename: Zhao-qun
authors.initials: ZQ
authors.lastname: Deng
authors.forename: Xiang-mei
authors.initials: XM
authors.lastname: Wen
authors.forename: Hong
authors.initials: H
authors.lastname: Guo
authors.forename: Ji-chun
authors.initials: JC
authors.lastname: Ma
authors.forename: Jiang
authors.initials: J
authors.lastname: Lin
authors.forename: Jun
authors.initials: J
authors.lastname: Qian
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000235:genetics; D022762:CCAAT-Enhancer-Binding Proteins / Q000235:genetics; D016022:Case-Control Studies; D004252:DNA Mutational Analysis; D015536:Down-Regulation; D005260:Female; D015973:Gene Expression Regulation, Leukemic; D006801:Humans; D053208:Kaplan-Meier Estimate; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000401:mortality / Q000628:therapy; D008297:Male; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D009154:Mutation; D011237:Predictive Value of Tests; D060888:Real-Time Polymerase Chain Reaction; D012074:Remission Induction; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D022762:CCAAT-Enhancer-Binding Proteins; C515848:CEBPA protein, human; C533096:MIRN186 microRNA, human; D035683:MicroRNAs